Preventing Cardiomyopathy in DMD: A Randomized Placebo-Controlled Drug Trial
Conclusions
Combination therapy was well tolerated. Consistent with the previous prophylactic perindopril heart study, there was no evidence of group benefit after 36-month treatment.
Classification of Evidence
This study provides Class I evidence that combination perindopril-bisoprolol therapy was well tolerated but did not change decline in LVEF significantly in boys with DMD.
Source: Neurology Clinical Practice - Category: Neurology Authors: Bourke, J. P., Watson, G., Spinty, S., Bryant, A., Roper, H., Chadwick, T., Wood, R., McColl, E., Bushby, K., Muntoni, F., Guglieri, M., for the DMD Heart Study Group Tags: Muscle disease, Clinical trials Randomized controlled (CONSORT agreement), All Pediatric, Cardiac; see Cerebrovascular Disease/Cardiac Research Source Type: research
More News: Bisoprolol | Boys | Brain | Cardiology | Cardiomyopathy | Clinical Trials | Electrocardiogram | Heart | Medical Ethics | Muscular Dystrophy | Neurology | Pediatrics | Reflex Sympathetic Dystrophy | Steroid Therapy | Study